Award
National Cancer Institute 5R01CA285726-02
CD200R blockade for cancer immunotherapy
Recipient
Ohio State University
Awarded
June 16, 2025
Identifier
5R01CA285726-02
NIH grant awarded by the National Cancer Institute for research on CD200R blockade in cancer immunotherapy, focusing on chemokine roles, T cell functions, and combination therapies.
Description
This NIH grant supports research on the role of CD200R in cancer immunotherapy, including evaluating chemokine roles, T cell functions, and potential combination therapies with angiogenesis inhibitors. The project involves multiple aims and studies to understand and improve cancer treatment strategies.